Fonkozomib 3.5 mg
Indonesia • Ferron Par Pharmaceuticals
Indication
Multiple Myeloma
Bortezomib for injection is indicated for the treatment of Multiple Myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy.
Mantle Cell Lymphoma
Bortezomib for injection is indicated for the treatment of patients with Mantle Cell Lymphoma who have received at least 1 prior therapy.
Multiple Myeloma – Combination therapy
Bortezomib in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated Multiple Myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Composition
Bortezomib 3.5 mg
Package
Dosage Forms
Powder for InjectionATC Classification
Warning
Dosage
18 Years Old and Above
Dosage in relapsed multiple myeloma and mantle cell lymphoma:
The recommended dose of bortezomib is 1.3 mg/m²/dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of bortezomib. It is recommended that patients receive 2 additional cycles of bortezomib following a confirmation of a complete response. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of bortezomib therapy.